Ceccanti, Mauro and Blum, Kenneth and Bowirrat, Abdalla and Dennen, Catherine A and Braverman, Eric R and Baron, David and Mclaughlin, Thomas and Giordano, John and Gupta, Ashim and Downs, Bernard W and Bagchi, Debasis and Barh, Debmalya and Elman, Igor and Thanos, Panayotis K and Badgaiyan, Rajendra D and Edwards, Drew and Gold, Mark S (2022) Future newborns with opioid-induced neonatal abstinence syndrome (NAS) could be assessed with the Genetic Addiction Risk Severity (GARS) test and potentially treated using precision amino-acid enkephalinase inhibition therapy (kb220) as a frontline modality instead of potent opioids. Journal of Personalized Medicine , 12 , (12) .